Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 May 2025 | Story Andre Damons | Photo Supplied
Prof Nyaga
Prof Martin Nyaga at the UFS-NGS Unit sequencing room giving a talk on the Illumina NextSeq 2000 with the P3 flow cell in hand.

The University of the Free State – Next Generation Sequencing (UFS-NGS) Unit hosted a pioneering scholarly engagement initiative for Grade 11 learners from nine secondary schools in Bloemfontein. The three-day event with the theme "Frontiers of Discovery: Illuminating the Impact of Genomics in Science outreach programme” marked the first comprehensive genomics science outreach initiative in the Faculty Health Sciences.

Coordinated by Prof Martin Nyaga, Head of the UFS-NGS Unit, the programme bridged the longstanding gap through practical NGS exposure and ignited a passion for Science, Technology, Engineering, and Mathematics (STEM) by inspiring the next generation of genomic innovators using combined interactive lectures, laboratory demonstrations, career talks, and hands-on workshops. This allowed learners to directly engage with cutting-edge scientific techniques and genomic technologies, especially the scientific and evolutionally impact of Polymerase Chain Reaction (PCR) and NGS.

The initiative engaged selected Grade 11 learners from the nine schools: Brebner, Ikaelelo and Vulamasango (day 1), Atlehang, Castle Bridge School and Kaelang (day 2) and Eunice, Navalsig, and Lekhulong (day 3).

“This outreach programme marks a significant milestone in community-based genomics education in South Africa by offering high school learners the opportunity to engage with modern genomic sciences before making career decisions. The initiative particularly aimed to nurture future scientists and diversify the country’s STEM talent pipeline.

“This historic programme bridged gaps in scientific literacy and diversity in the Free State and concluded each day with a genomics quiz competition, which tested the participant’s newly acquired knowledge/exposure and provided a fun competitive learning opportunity. Six quiz winners across the three days received special prizes, and all students were awarded certificates of participation,” says Prof Nyaga.

 

Hands-on exploration and NHLS virology laboratory tour

The training was held at the UFS-NGS Unit in the School of Biomedical Sciences and at the NHLS Virology laboratories, School of Pathology, Faculty of Health Sciences. Each attending secondary school was represented by five Grade 11 learners and a life science’s educator. Each day, 15 learners and three educators observed hands-on practicals, including DNA extraction, PCR, gel electrophoresis, and DNA library preparation for sequencing on platforms such as Illumina MiSeq and NextSeq 2000.

Guided by the UFS-NGS Unit’s team members; Dr Milton Mogotsi, Hlengiwe Sondlane, Mbali Ncube, Nkosazana Shange, Somila Nazo, Sesiyanda Maseko, Surprise Baloyi, Manyi Eyong and Mamello Maku, the learners were exposed to how DNA is extracted and visualised, how the PCR machine works and how DNA libraries are prepared and sequenced.

Furthermore, a guided laboratory tour of the Virology laboratories at the NHLS was provided by Khauhelo Mafa which offered the leaners the opportunity to observe, diagnostic and molecular workflows in action, resulting in a real-time glimpse into world-class medical research and diagnostics, fuelling curiosity about the role of advanced genomics science in disease control.

 

Inspiration through expert talks

The learners were also inspired by talks from Prof Chris Viljoen, Head of the School of Biomedical Sciences, Prof Zinhle Makatini, Associate Professor and Head of Division of Virology, School of Pathology, and Dr Claudia Ntsapi, Senior Lecturer and researcher in the Department of Basic Medical Sciences at the UFS. Prof Viljoen highlighted the role of science in transforming lives and improving life expectancy, while Prof Makatini gave candid reflections on her professional journey, particularly how she pursued Medical Virology through unwavering determination and excelled to become among the pioneer women specialists in the field in South Africa. Dr Ntsapi inspired the audience with her perseverance from her humble beginnings to earning a PhD in Neurophysiological Sciences against all odds.

The speakers also delivered compelling presentations on the applications of genomics in medicine (e.g.), personalised cancer treatments), public health (e.g.), tracking HIV and COVID-19), agriculture (e.g.), resilient crops), and environmental science (e.g.), ecosystem protection), which resonated well with the learners, educators and the UFS-NGS team. A presentation on diverse career options available at the UFS Faculty of Health Sciences was further provided by Angelique Carson-Porter, a UFS representative from the Department of Nutrition & Dietetics. Her talk on different career pathways in Health Sciences broaden the learners’ horizons, fostering future aspirations.

Dr Emmanuel Ogunbayo, Dr Mogotsi, Thabisa Mpaxa, Nkosazana Shange and Eyong Manyi shared their personal career journey to be at the UFS-NGS Unit, offering advice on academic experiences and opportunities within genomics, bioinformatics, and biotechnology, while answering scholarship queries.

“The career talk opened my eyes. I’m now aiming for a biotechnology degree!” said Neliswa Thwala, a learner from Navalsig CS/S.

Following the enthusiastic response and tangible outcomes of this programme, the UFS-NGS Unit is committed to expanding this initiative, with plans to introduce similar events to other schools and developing sustained mentorship opportunities for learners interested in pursuing genomics-related careers. The UFS-NGS Unit further invites interested partners, sponsors, and stakeholders to collaborate in future outreach and capacity-building programmes to continue bridging the genomics education gap in Africa.

 

Inspire the next generation

Prof. Nyaga’s closing remarks highlighted the learners’ potential to shape the ‘omics’ workforce and stated the intention of the organising committee to expand the mentorship programmes, fostering a vibrant STEM pipeline. “This initiative represents our vision to make genomics accessible and inspire the next generation of African scientists.”

The success of this programme was driven by the UFS-NGS Unit team and was supported by Distribution Platform in Omics (DIPLOMICS).

  • For more information about the UFS-NGS Unit or future outreach programmes, please visit our website. Further pictures from the event are also available via our website.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept